Intellectual Product

Alumis’ TYK2 Inhibitor Envudeucitinib Succeeds in Phase 3 Psoriasis Trials, Plans FDA Filing

19 hours ago talkbio0Tagged Alumis, Approved, envudeucitinib, Phase 3 trials, Psoriasis, Psoriasis Area and Severity Index Clinical Classification, TYK2 Inhibitor, United States Food and Drug Administration

Alumis; envudeucitinib; TYK2 inhibitor; psoriasis; Phase 3 trials; FDA approval; PASI 75

Innovative Solutions for Difficult-to-Express Proteins: Cell-Free Systems and AI-Driven Advances

6 days ago talkbio0Tagged AI protein design, Alternative, Cell-free protein, Difficult-to-Express Proteins, Gene Expression, In Vitro [Publication Type]

cell-free protein expression; difficult-to-express proteins; AI protein design; in vitro expression; alternative proteins

Breakthrough Real-World Evidence Powering Blood Cancer Research in 2025

2 weeks ago talkbio0Tagged Asymmetric Septal Hypertrophy, hematologic care, Hematologic Neoplasms, real-world evidence, Real-world Evidence, SOHO

RWE; blood cancer; real-world evidence; ASH 2025; SOHO 2025; hematologic care

Endpoints News Topics at 2026 JPM Healthcare Conference: CEOs, Investors, China, and Beyond

3 weeks ago talkbio0Tagged AI healthcare, Biopharma, CEOs, Endpoints, investors, JPM Healthcare Conference, News [Publication Type], Private Equity

JPM Healthcare Conference; Endpoints News; CEOs; investors; AI healthcare; biopharma; private equity

Quantori and Expert Systems Partner to Accelerate Drug Discovery with Foundational Predictive AI Models

3 weeks ago talkbio0Tagged AI models, Dosage Forms, Drug Discovery, Expert Systems, Q-Scientist, Quantori, R&D

Quantori; Expert Systems; drug discovery; AI models; Q-Scientist; pharmaceutical R&D

Biopharma’s Winners and Losers of 2025 – Endpoints News recap

3 weeks ago talkbio0Tagged 2025, Biopharma, Endpoints, Kyle LaHucik, Losers, movers, News [Publication Type], Pharma, Post-Hoc Live, Review [Publication Type], winners

Endpoints News; winners and losers; 2025; biopharma; Post-Hoc Live; Kyle LaHucik; year in review; biotech; pharma; stock movers

No public results for “Take the Biopharma Sentiment Index” Q1 2026 yet

3 weeks ago talkbio0Tagged Attitude, Biological Science Disciplines, Biopharma, biopharma executives, Biopharma Sentiment Index, geopolitical risk, M&A activity, Q1 2026, Sentiment, Surveys

Biopharma Sentiment Index; Q1 2026; biopharma executives; life sciences sentiment; 2026 outlook; M&A activity; AI in biopharma; geopolitical risk; survey data

FDA Advances Real-World Data Use and Early-Phase Trial Reforms to Accelerate Drug Approvals

3 weeks ago talkbio0Tagged Drug Approval, early-phase trials, real-world data, real-world evidence, Real-world Evidence, RWE, Transplant Registry Unified Management Program, Trump, United States Food and Drug Administration

FDA; real-world data; real-world evidence; RWE; early-phase trials; drug approval; Marty Makary; Trump

Sanofi’s multiple sclerosis drug tolebrutinib flunks Phase 3 in PPMS and faces another FDA PDUFA delay

3 weeks ago talkbio0Tagged BTK inhibitor, Clinical trial failure, Deferred, Mississippi (geographic location), Multiple Sclerosis, non-relapsing secondary progressive, nrSPMS, Parts per million (qualifier value), PDUFA, Progressive, Regulatory Setback, Review [Publication Type], sanofi, Tolebrutinib, United States Food and Drug Administration

Sanofi; tolebrutinib; multiple sclerosis; primary progressive multiple sclerosis; PPMS; non-relapsing secondary progressive MS; nrSPMS; Phase 3 PERSEUS trial; PDUFA delay; FDA review; BTK inhibitor; clinical trial failure; regulatory setback

Spotlight On: It’s Raining AI Devices as Regulatory Storm Reshapes Digital Health

4 weeks ago talkbio0Tagged 2025, Accountability, AI-enabled, clinical oversight, digital health regulation, digital mental health devices, draft guidance, EU, EU AI Act health, Generative AI, Health care facility, Medical Devices, Regulation, Software as a Medical Device, United States Food and Drug Administration

AI-enabled medical devices; digital health regulation 2025; FDA AI draft guidance; EU AI Act health; generative AI in healthcare; SaMD regulation; clinical oversight of AI; AI accountability in healthcare; digital mental health devices